Researchers continue to find evidence that the combination of lopinavir/ritonavir (Kaletra) provides prolonged potency while avoiding drug resistance. The Kaletra findings come on the heels of another study that found a high rate of drug resistance among HIV patients with measurable levels of virus in their blood.